N30 Pharma is developing s-nitrosothiol therapies for critical unmet needs in respiratory diseases such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease. A Phase I study of their lead molecule N30-201 used in healthy volunteers has been successfully completed. Safety and adverse events were characterized in addition to collecting pharmacokinetic and pharmacodynamic data of [...]